|
A.U.k. Kazimova, Sh.M.k. Polukhova
Pharmacotherapeutic aspects of gestational diabetes mellitus against the background of impaired maternal immunity
|
№4-5 / 2023
|
|
A.E. Bagriy, E.S. Mikhailichenko, A.V. Prikolota, K.E. Mogilevskaya
Features of the pathogenesis and treatment of diabetes mellitus during the COVID-19 pandemic
|
№11-12 / 2022
|
|
L.Yu. Morgunov
Type 3 diabetes mellitus: is there a chance to become famous?
|
№4 / 2022
|
|
E.Yu. Smirnova
Time is more precious than gold. Choosing a strategy for the successful management of a patient with suspected LADA-diabetes (clinical case)
|
№12 / 2021
|
|
O.S. Elsukova, A.A. Sobolev
ADVANTAGES OF SWITCH TO PREMIXED INSULIN DEGLUDEC/ ASPART IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE NOT ACHIEVED AN OPTIMAL CONTROL WITH PREVIOUS INSULIN THERAPY
|
№16 / 2017
|
|
M.B. Antsiferov
THE USE OF INSULIN GLARGINE 300 IU/ML (TOUJEO SOLOSTAR®) IN REAL CLINICAL PRACTICE
|
№16 / 2017
|
|
M. V. Shestakova, M. B. Antsiferov, OK Vikulova
Biosimilars: Substitution Problems And Modern Requirements For A Generic Insulin Preparations
|
№5 / 2013
|
|
S.V. Nedogoda
Insulin Resistance And High Blood Pressure - Two Goals Of Antihypertensive Therapy
|
№17 / 2012
|
|
A.F. Verbovoy 1, E.I. Vorozhtsova 1, T.N. Orlova 2
Metabolic Parameters In Men With Type 2 Diabetes Mellitus And Coronary Artery Disease
|
№9 / 2012
|
|
V.A. Peterkova
Diabetes In Children And Adolescents: To The 90th Anniversary Of The Introduction Of Insulin In Clinical Practice
|
№3 / 2012
|
|
M.B. Antsiferov
Application Of Vildagliptin In Combination With Insulin In Type 2 Diabetes Mellitus
|
№3 / 2012
|
|
A.F.Verbovoy, I.A. Fomina
Endocrine-metabolic Indices And Leptin In Young Men With Obesity, Manifesting In Puberty
|
№16 / 2010
|
Русский
